Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Pfizer

The Centers for Disease Control and Prevention still has to issue its recommendations before pharmacies can administer the new shots to kids.

FDA authorizes Covid omicron booster shots for kids as young as 5 years old

Merck

Merck opted Wednesday to help Moderna develop a personalized cancer vaccine based on messenger RNA technology, and MRNA stock rocketed. The post Moderna Surges As Merck Inks Deal To Co-Develop Personalized Cancer Vaccine Treatment appeared first on Investor's Business Daily.

Moderna Surges As Merck Inks Deal To Co-Develop Personalized Cancer Vaccine Treatment

Advanced Micro Devices

Generac Holdings

Lam Research

Monolithic Power Systems

NVIDIA

QUALCOMM

Signature Bank

Bio-Techne

Seeing S&P 500 growth stocks implode is tough to watch, unless you're ready to spot a buy point. The post 10 Fallen Growth Stocks Will Make You Up To 113% Richer, Analysts Say appeared first on Investor's Business Daily.

10 Fallen Growth Stocks Will Make You Up To 113% Richer, Analysts Say

Merck & Co. Inc. MRK, +0.63% and Moderna Inc. MRNA, -2.19% said Wednesday that they plan to jointly develop and commercialize a personalized cancer vaccine. The investigational vaccine is currently being tested in a Phase 2 clinical trial as a treatment for patients with high-risk melanoma in combination with Merck's Keytrduda, an anti-PD-1 therapy that has been approved to treat several types of cancer.

Merck, Moderna to develop personalized cancer vaccine

Merck & Co Inc opted to jointly develop and potentially sell a personalized mRNA vaccine with Moderna Inc for a $250 million upfront payment on Wednesday, sending the vaccine maker's shares up over 8%.

Merck opts to develop, sell cancer vaccine with Moderna

Companies on track to report data from the ongoing Phase 2 trial of mRNA-4157/V940 in combination with KEYTRUDA® as adjuvant therapy in high-risk melanoma in 4Q 2022 CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / October 12, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Merck has exercised its option to jointly develop and commercialize personalized cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing Collaboration and License Agreement. mRNA-4157/V940 is currently being evaluated in combination with KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant treatment for patients with high-risk melanoma in a Phase 2 clinical trial being conducted by Moderna.

Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine

Amazon

H&R Block

Block

Uber

Alphabet

Although the red ink splashed on the equities sector has many bulls in the dumps, it's also important to remember that the doldrums open opportunities for these 7 stocks to buy on the dip. To be fair, you don't want to just react to volatility in a simplistic Pavlovian manner.

Smart Investors Will Be Buying All the Dips for These 7 Stocks

Axsome Therapeutics

Both of these biotechs offer exciting future prospects.

Better Buy: Moderna vs. Axsome Therapeutics

NIKE

Tesla

These leaders look cheap, considering their growth prospects.

Get Ready for the Next Bull Market: 3 Stocks to Buy Right Now

The CDC's latest report on COVID-19 vaccinations didn't provide enough fuel for shareholder optimism.

Why Moderna Stock Couldn't Shake the Thursday Blues

As a $48B market cap company, Moderna delivers a highly efficacious/safe vaccine for COVID. The company is also advancing a pipeline of both vaccines and therapeutics that are highly promising.

Moderna: A Great Diversification Into Large Cap

Is Moderna stock a buy after asking the FDA signed off on its BA.4- and BA.5-tailored Covid booster? Is MRNA stock a buy now?

Is Moderna Stock A Buy After FDA Signs Off On Its Updated Covid Shot?

Pubmatic

Investment bank analysts think both of these stocks have what they need to deliver big gains in the foreseeable future.

2 Growth Stocks That Could Jump 64.1% to 86.1% Higher, According to Wall Street

General Motors

Netflix

Gap Inc

Peloton

Stanley Black & Decker

There's a saying in investing, attributed to Warren Buffett, that you don't see who's swimming naked until the tide goes out.  Essentially, this means that poorly run and troubled companies are most exposed during market downturns.

7 S&P 500 Stocks to Sell Before They Die

Moderna has so far refused to make a deal for its COVID-19 vaccine with China, due to Beijing wanting the intellectual property behind it.

Moderna turns down China request for vaccine technology: report

Moderna Inc has refused to hand over to China the core intellectual property behind the development of its COVID-19 vaccine, leading to a collapse in negotiations on its sale there, the Financial Times reported on Saturday, citing people familiar with the matter.

Moderna refused China request to reveal vaccine technology, Financial Times reports

Moderna's billion-dollar revenue may be just getting started.

Here's Why the Post-Pandemic World May Be Even Better for This Vaccine Maker

A shuffle at the top of the executive ranks, combined with the continued decline of the coronavirus, rattles some investors.

Why Moderna Was a Sickly Stock Today

The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222, designed to target the Omicron BA.4 and BA.5 subvariants.

EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster

Novavax

These vaccine makers have lost much of the momentum they built earlier in the pandemic.

These 2 Growth Stocks Have Fallen Out of Grace. Are They Buys?

Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion Jerh Collins Joins Moderna as Chief Technical Operations and Quality Officer to Succeed Juan Andres CAMBRIDGE, MA / ACCESSWIRE / September 29, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the Company has expanded the Executive Committee to prepare for multiple upcoming new product launches. Effective January 1, 2023, Juan Andres will step into a new role as President, Strategic Partnerships and Enterprise Expansion, and will focus on building out the organization to support the growing pipeline.

Moderna Creates New Executive Committee Role Ahead of New Product Launches

The company's latest regulatory advance is overshadowed by developments with another biotech.

Why Moderna Stock Lagged the Market Today

Apple

Coupang

DraftKings

Perficient

Tenable Holdings Inc

In this market slowdown there appear to be fewer growth stocks to buy, but patience will be rewarded. It's been a forgettable year, to say the least, for equity investors.

7 Growth Stocks to Buy Before the Bull Market Returns

Investors cheered some positive news on the vaccine supply front.

Why Moderna Stock Crushed the Market Today

Gilead Sciences

Covid-related product sales helped make BioNTech SE ( BNTX , Financial), Moderna Inc. ( MRNA , Financial), Gilead Sciences Inc. ( GILD , Financial) and Regeneron Pharmaceuticals Inc. ( REGN , Financial) the most productive biopharma companies in 2021, according to a Fierce Pharma ranking.

News for Moderna Stock (MRNA)